A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

HER2-positive Breast Cancer Clinical Trial

— Affibody-3  

Official title:

A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03655353
• Other study ID #: ABY-025-MI301
• Status: Recruiting
• Phase: N/A
• Start date: August 22, 2018
• Est. completion date: November 1, 2025

Study information

• Verified date: September 2021
• Source: Uppsala University Hospital
• Contact: Lena Franklin, BSc
• Phone: +46 18 6111761
• Email: lena.franklin[@]akademiska.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 68Ga-ABY-025 PET and standard histopathology from relevant tumor biopsies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: November 1, 2025
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent.

2. Age =18 years.

3. Histologically or cytologically confirmed HER2-positive or borderline positive (for definition see below) adenocarcinoma of the breast.

HER2-positive defined as:

1. 3+ by immunohistochemistry [IHC] in >10% of cell areas.

2. 2+ by IHC in >10% of cell areas and HER2/CEP17 ratio =2.0 or HER2 copy number = 6.0 by in situ hybridization [ISH]).

HER2-borderline positive defines as:

3. 2+ by IHC and HER2/CEP17 ratio <2.0 and/or HER2 copy number 4.0 - 6.0 by in situ hybridization [ISH]) ("equivocal").

4. 2+ by IHC and HER2/CEP17 ratio <2.0 and/or HER2 copy number <4.0 by in situ hybridization [ISH]) ("2+ ISH negative").

5. Known inhomogeneous HER2-expression in the primary tumor with HER2-positive areas <10% ("inhomogeneous").

4. Primary breast cancer planned for neoadjuvant therapy (Stage II-III, T2-4N0-3) or metastatic (M1; at least 80 pts).

5. At least one tumor lesion = 10 mm.

6. At least one tumor lesion available for biopsy.

7. Newly diagnosed or confirmed progression and planned for therapy with trastuzumab emtansine or anti-HER2 targeted therapy(-ies) concomitant with chemotherapy (HER2-positive cohort) or chemotherapy (HER2-negative patients).

8. WHO performance status = 2.

9. Predicted survival > 12 weeks.

10. Negative pregnancy test in women of childbearing potential (premenopausal or <12 months of amenorrhea post-menopause and who have not undergone surgical sterilization). Women of childbearing potential must use highly effective method of contraception, i.e combined hormonal contraception, or progestogen-only hormonal contraception, or intrauterine device, or intrauterine hormone-releasing system, or bilateral tubal occlusion, or vasectomized partner, or sexual abstinence

Exclusion Criteria:

1. Histologically or cytologically confirmed HER2-negative breast cancer defined as IHC 0 or 1+.

2. Other manifest malignancy.

3. Serious uncontrolled concomitant disease including congestive heart failure that would contraindicate the use of any anti-HER2 therapy.

4. Inadequate organ function, suggested by the following laboratory results:

• Absolute neutrophil count <1,500 cells/mm3

• Total bilirubin =1.5 x ULN (unless the patient has documented Gilbert's syndrome)

• AST (SGOT) or ALT (SGPT) >5.0 × ULN

• Serum creatinine clearance <30 ml/min

5. Patients of childbearing potential and sexually active and not willing to use highly effective contraceptive.

6. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2-positive Breast Cancer

Intervention

Diagnostic Test:
• ABY-PET
Diagnostic PET for HER2 expression

Locations

Country	Name	City	State
Sweden	Section for Clinical Research & Development Unit	Uppsala

Sponsors (5)

Lead Sponsor	Collaborator
Henrik Lindman	Affibody, Roche Pharma AG, Swedish Breast Cancer Group, Swedish Cancer Society

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HER2- expression by using 68Ga-ABY-025 PET.	HER2-expression in tumors measured by 68Ga-ABY-025 PET, centrally analysed and result used for location of biopsy.	Approximately 10 days after study entry.
Primary	HER2-expression by analysing biopsy sample.	HER2-expression in tumors by histopathology. Location of biopsy site based on HER2 expression seen in ABY-PET.	Approximately 21 days after study entry.